IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3540-3542

  Jacquet, Antoine ^a   Francois, Helene ^a   Frangie, Carlos ^a   Yahiaoui, Yasmina ^a   Ferlicot, Sophie ^a   Micelli, Corinne ^a   Mariette, Xavier ^a   Durrbach, Antoine ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Ankylosing spondylitis; IgA nephropathy; Infliximab; TNFalpha

Indexed keywords

INFLIXIMAB; IRBESARTAN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEINURIA; DRUG ANTAGONISM;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73949138421     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp314     Document Type: Article

References (12)

1. Verschueren P, Lensen F, Lerut E, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003; 62: 368-369
2. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritis: a follow up report of tolerability and efficacy. Arthritis Rheum 2003; 48: 2019-2024
3. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 1998; 17: 524-530
4. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748
5. Montenegro V, Monteiro RC. Elevation of serum IgA in spondy- loarthropathies and IgA nephropathy and its pathogenic role. Curr Opin Rheumatol 1999; 11: 265-272
6. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104: 73-81
7. Haddad E, Moura IC, Arcos-Fajardo M, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14: 327-337
8. Chan LY, Leung JC, Tsang AW, et al. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 2005; 67: 602-612
9. Leung JC, Tang SC, Chan LY, et al. Synthesis of TNF-alpha by mesan-gial cells cultured with polymeric anionic IgA-role of MAPK and NF-kappaB. Nephrol Dial Transplant 2008; 23: 72-81
10. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998; 9: 433-438
11. Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 2007; 26: 1132-1133
12. Saint-Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006; 73: 710-713